Cell Therapeutics Announces Resignation of Chief Medical Officer
News Jul 01, 2013
Cell Therapeutics, Inc. has announced the resignation of Steven E. Benner, M.D., M.H.S., Senior Vice President, Chief Medical Officer and Chief Compliance Officer for personal reasons.
Nancy Boman, M.D., Ph.D., Senior Vice President, Clinical Development and Regulatory Affairs, is expected to assume interim responsibility for the oversight of CTI's ongoing and planned clinical trials of compounds for the treatment of blood cancers.
CTI has engaged a search firm to assist in an external search for a new Chief Medical Officer and will appoint a new Chief Compliance Officer.
Immediately prior to his resignation, based on public records, Dr. Benner beneficially owned 396,705 shares of CTI's common stock.
"Steve has established a strong leadership team in the clinical organization that is focused on advancing our two ongoing late-stage clinical programs for pacritinib and PIXUVRI® (pixantrone). We acknowledge and thank Steve for his significant contributions to these programs and wish him the very best in his future endeavors," said James A. Bianco, M.D., President and CEO of CTI.
Dr. Bianco added, "As we move toward initiating the second planned Phase 3 clinical trial evaluating pacritinib, our JAK2/FLT3 inhibitor for the treatment of patients with myelofibrosis later this year, we are confident that the clinical and regulatory team we have in place will continue to execute and our development plans will remain on track."
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Investigational Drug for Melanoma Shows Promise in Early-Stage StudyNews
An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.READ MORE
‘Mini Tumors’ from Patient Samples Could Help Personalize Cancer Drug TreatmentNews
Testing cancer drugs on miniature replicas of a patient’s tumour could help doctors tell in advance which treatments will work, a major new study reports.READ MORE